Project Grant R41CA281511
Award Date
9/20/23
Completion Date
8/31/24
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $622,329 to Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1I and evaluate its ability to prevent metastasis and sensitize triple-negative breast cancer (TNBC) to chemotherapies. The award, which runs from August 2024 to July 2029, supports experiments to formulate PDZ1I into a nanocrystal (PDZ1I-nano) for clinical use, characterize how PDZ1I impacts the immune...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $781,436 to Cold Spring Harbor Laboratory to conduct research aimed at optimizing anti-NMDAR antibodies as a therapy for triple-negative breast cancer (TNBC). The key products and services to be delivered under this award include: Establishing an orthotopic mouse model of NMDAR-positive TNBC to study the anti-tumor effects and toxicity of anti-NMDAR antibodies (Aim 1). Isolating and...
This $400,000 Project Grant award from the National Cancer Institute's (CFDA 93.395) Cancer Treatment Research program aims to activate the transcription factor EB (TFEB) in order to enhance the efficacy of immunotherapy for triple-negative breast cancer (TNBC). The funded research will evaluate the toxicity and pharmacokinetic properties of the TFEB activator compound USCYL01, as well as test its ability to improve the efficacy of immune checkpoint inhibitor (ICI) therapy combined with...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The University of Kentucky Research Foundation to identify and target the enzyme nicotinamide N-methyltransferase (NNMT) as a novel approach to treat triple-negative breast cancer (TNBC). The $631,492 award will support a 5-year research project to: 1) define how NNMT promotes TNBC survival and metastasis by enabling cancer cells to withstand oxidative stress, 2) evaluate the...
This $524,419 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the molecular basis of fatty acid synthase (FASN) inhibition and its impact on overcoming resistance to PARP inhibitors (PARPi) in triple-negative breast cancer (TNBC). The project will: 1) determine the molecular mechanism by which proton pump inhibitors (PPIs) inhibit FASN, 2) elucidate how FASN contributes to PARPi resistance by regulating PARP1 and BRCA1...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) totaling $619,764 aims to develop new combination immunotherapy strategies to enhance the anti-tumor efficacy against triple-negative breast cancer (TNBC). The award will fund research to: Increase tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor delivery system (P-aPDL1) by triggering local thrombus formation at the TNBC site using a truncated tissue...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to the University of California, Davis is focused on developing a novel therapeutic strategy to target mutant p53, a tumor suppressor gene that is mutated in over half of human cancers. The $590,625 award, effective March 1, 2025 through February 28, 2030, supports research with the following key objectives: Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...